Answers are grounded in this paper and cite their sources.
BACKGROUND: Circulating immune-related analytes have been investigated as correlates of clinical severity in alopecia areata (AA) and vitiligo. OBJECTIVE: To evaluate serum zonulin immunoreactivity, CXCL10 and S100P across clinical groups and in relation to severity, with an exploratory assessment of discrimination. METHODS: In a single-center cross-sectional cohort of 90 adults (30 AA, 30 vitiligo and 30 healthy participants), commercial sandwich ELISA results were assessed by nonparametric group comparisons, age- and sex-adjusted models and Spearman correlations with false-discovery-rate correction. Corrected ELISA summaries used 27 healthy-control assay records and excluded one nonquantifiable vitiligo zonulin result. Receiver operating characteristic (ROC) analyses were conducted on the available participant-level biomarker workbook. RESULTS: No analyte differed significantly across groups after multiplicity correction (all q > .05). Zonulin immunoreactivity and CXCL10 correlated positively with SALT in AA (r_s = .692 and .732) and VASI in vitiligo (r_s = .793 and .492); S100P did not. CXCL10 yielded the highest observed ROC discrimination for vitiligo against healthy controls (AUC 0.675, 95% bootstrap CI 0.527-0.815), with modest apparent sensitivity and specificity. CONCLUSION: The observed biomarker-severity relationships are cross-sectional and exploratory. The present ROC results and commercial zonulin immunoreactivity cannot establish diagnostic or monitoring utility, intestinal permeability, or causality.
No takes yet. Share an insight, caveat, or question.
Al-Khafaji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: